| Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.090 | Biomarker | disease | BEFREE | The insulin-like growth factor-I receptor and its role in thyroid-associated ophthalmopathy. | 30385883 | 2019 | ||||
|
0.090 | Biomarker | disease | BEFREE | Thus, TSHR must neighbor IGF1R for crosstalk in GO fibroblasts to occur, and this depends on ARRB1 acting as a scaffold. | 31127272 | 2019 | ||||
|
0.090 | Biomarker | disease | BEFREE | The recent completion of phase 2 and 3 randomized, placebo-controlled trials demonstrate the efficacy and safety of teprotumumab, a fully human monoclonal IGF-1R antagonist antibody, in patients with moderate-to-severe, active TED. | 31377284 | 2019 | ||||
|
0.090 | Biomarker | disease | BEFREE | Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' disease and Graves' orbitopathy. | 30132285 | 2019 | ||||
|
0.090 | Biomarker | disease | BEFREE | Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy. | 30215690 | 2019 | ||||
|
0.090 | Biomarker | disease | BEFREE | Inhibiting thyrotropin/insulin-like growth factor 1 receptor crosstalk to treat Graves' ophthalmopathy: studies in orbital fibroblasts in vitro. | 27987211 | 2017 | ||||
|
0.090 | Biomarker | disease | BEFREE | Teprotumumab (TMB) is a human monoclonal IGF-1R blocking antibody currently in clinical trial for GO and inhibits TSHR-mediated actions in FCs. | 26087256 | 2015 | ||||
|
0.090 | GeneticVariation | disease | LHGDN | Unique attributes of orbital fibroblasts and global alterations in IGF-1 receptor signaling could explain thyroid-associated ophthalmopathy. | 18788919 | 2008 | ||||
|
0.090 | Biomarker | disease | LHGDN | The observation that hyaluronan production is induced by GD-IgG in fibroblasts suggests that the IGF-I receptor and its activating antibodies may represent a key pathway through which important pathogenic events in thyroid-associated ophthalmopathy are mediated. | 15472208 | 2004 |